Are you Dr. Morris?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Gilman Dr
"# MC0612"
La Jolla, CA 92093Phone+1 858-822-3490
Summary
- Dr. Gerald Morris, MD is a board certified pathologist in La Jolla, California. He is currently licensed to practice medicine in California. He is an Instructor at Washington University School of Medicine.
Education & Training
- Wayne State University School of MedicineClass of 2006
Certifications & Licensure
- CA State Medical License 2013 - 2027
- CA State Medical License 2013 - 2027
- American Board of Pathology Pathology - Clinical
Publications & Presentations
PubMed
- 3 citationsThe Impact of HLA-DQαβ Heterodimer Mismatch on Living Donor Kidney Allograft Outcomes.Olga Charnaya, Tanveen Ishaque, Andrew Hallett, Gerald P Morris, Myra Coppage
Transplantation. 2025-04-01 - Surveillance donor-specific antibody and pathologic antibody-mediated rejection testing in heart transplant patients in the contemporary era.Vincenzo Cusi, Ashley Cardenas, Yuko Tada, Florin Vaida, Nicholas Wettersten
The Journal of Heart and Lung Transplantation. 2025-02-04 - Follow-up biopsies with microvascular inflammation and persistent donor specific antibodies identify ongoing rejection in pediatric kidney transplant recipients.Clarkson Crane, Janara Mehrabli, Natalie Ellington, Katayoon Shayan, Gerald P Morris
Pediatric Nephrology. 2025-01-28
Grant Support
- Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplantUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2026
- Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplantUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2026
- Dual TCR Expression Effects on Alloreactivity and TransplantationUNIVERSITY OF CALIFORNIA, SAN DIEGO2020–2025